Cancer Guidelines Database

This is a clinical practice guideline for women with a pathogenic or likely-pathogenic variant in their BRCA1 and BRCA2 genes. The guideline examines risk reduction strategies for this patient population, including screening, risk-reducing surgery, hormone therapy, surveillance, and more. The primary outcomes of interest are the prevention and early detection of cancers of the ovary and breast.

This is a clinical practice guideline for adult patients with solid tumours or lymphoid blood cancers, and is especially relevant to those receiving chemotherapy. The guideline examines the use of myeloid growth factors (MGFs) for the prevention and management of neutropenia and anemia in these patients. Specific topics addressed include red blood cell transfusion, erythropoietic therapy, as well as iron monitoring and supplementation.

This is a clinical practice guideline for adult cancer patients who are being treated with EGFR inhibitors, either alone or in combination with other treatments. The guideline provides recommendations for the prevention and treatment of acneiform rash in these patients. Specific topics of interest include grading of rash severity and looking into the relationship between rash and treatment response.

This is a clinical practice guideline for patients undergoing potentially cardiotoxic oncological treatment, including chemotherapy, targeted therapy and radiotherapy. The guideline examines various prevention, detection, treatment and monitoring strategies available for reducing cardiovascular toxicity in these patients. Outcomes of interest include cardiovascular morbidity, and mortality.

This is a clinical practice guideline for adult cancer patients who are receiving immunotherapy as part of their treatment. The guideline provides recommendations for the management of immune-related adverse events (irAEs) in these patients. Immunotherapy agents discussed include atezolizumab, ipilimumab, nivolumab, pembrolizumab, avelumab, durvalumab, and cemiplimab.

This is a clinical practice guideline for adults with suspected or confirmed renal cell carcinoma. The guideline provides recommendations on the diagnosis, staging and classification, prognosis, treatment, and follow-up of these patients. This a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 24th, 2021.

This is a clinical practice guideline for adult cancer survivors with, or at risk for developing, chemotherapy-induced peripheral neuropathy (CIPN). The guideline examines prevention and treatment approaches in the management of chemotherapy-induced neuropathies. Various agents and interventions are assessed in the prevention of CIPN. Treatment recommendations are divided between patients who are receiving neurotoxic chemotherapy and patients who have completed neurotoxic chemotherapy.

This is a clinical practice guideline on the prevention and cessation of tobacco use in school-aged children and adolescents (< 18 years). The guideline examines the effectiveness of medication for smoking cessation, as well as the effectiveness of various primary care behavioural interventions, including print, face-to-face, telephone, and computer-based interventions.

This is a clinical practice guideline for patients with polyposis syndromes, including familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), and serrated polyposis syndrome (SPS). The guideline provides recommendations on endoscopic surveillance and interventions for these patients. The primary outcomes of interest are reductions in colorectal cancer incidence and mortality.

This is a clinical practice guideline for bowel preparation prior to colonoscopy procedures. The guideline examines appropriate preparation methodologies for adult patients, including special populations such as patients who are pregnant/lactating, patients with inflammatory bowel disease (IBD) and elderly people. Outcomes of interest include adverse events, postoperative complications and postoperative morbidity.

This is a clinical practice guideline for adult patients who are at an increased risk of developing gastric adenocarcinoma, specifically those with gastric atrophy (GA), gastric intestinal metaplasia (GIM), gastric epithelial dysplasia or early gastric adenocarcinoma limited to the mucosal or superficial submucosal layers. The guideline provides recommendations for the diagnosis and management of these patients, while addressing specific topics such as Helicobacter pylori eradication, endoscopic screening, and endoscopic mucosal resection.

This is a clinical practice guideline for the management of infusion reactions (IR) caused by cancer medication. The guideline examines prophylaxis, acute management of IRs, as well as re-start and re-challenge protocols. Outcomes of interest include treatment toxicity, adverse events, and the incidence and severity of IRs.

Tailored to the unique needs and concerns of patients with all types of cancer, this clinical practice guideline provides standard-of-care recommendations, techniques, and strategies on smoking cessation. The guideline outlines different interventions, including pharmacotherapy options (e.g. nicotine replacement therapy, varenicline, bupropion, nortriptyline, clonidine), motivational strategies and behaviour techniques, and alternative treatment approaches such as electronic cigarettes and other electronic nicotine delivery systems.

This is a clinical practice guideline for adults with appendiceal neoplasms, excluding GI stromal tumours, lymphomas, and neural proliferations. The guideline provides recommendations on the management of these patients. Specific topics discussed include colonoscopy, pre-operative assessment, appendectomy, biochemical testing, and post-operative surveillance. Outcomes of interest include recurrence rate of neoplasms and disease-free survival.

This is a clinical practice guideline for patients with a higher risk of developing colorectal cancer (CRC), specifically, those with Lynch syndrome (LS) and/or familial risk of CRC. The guideline provides a framework for the endoscopic management of individuals with LS, and proposes a definition of familial risk of CRC to identify the group of individuals in whom colonoscopy surveillance is justified. Colonoscopy surveillance, quality standards, starting age, surveillance intervals and advanced imaging techniques are also addressed.

This is a clinical practice guideline for reducing the risk of breast cancer. The guideline examines the use of potential risk-reducing medications such as tamoxifen, raloxifene, or aromatase inhibitors in asymptomatic women over 35 years of age, including women with previous benign breast lesions identified via biopsy. Outcomes of interest include breast cancer risk-reduction, and adverse effects from preventive medications.

This is a clinical practice guideline examining the routine vaccination of children with cancer, during and after completion of chemotherapy. The guideline specifically discusses the use of vaccines for hepatitis B, hepatitis A, diphtheria, tetanus, pertussis, polio, Hemophilus influenzae, measles, mumps, rubella, influenza, meningococcus, pneumococcus, varicella, human papilloma virus (HPV), and rotavirus.

This is a clinical practice guideline on breast cancer in adult patients. The guideline examines endocrine therapy as a risk-reduction intervention in patients who are at increased risk of developing the disease but have not been previously diagnosed. Various interventions are examined while taking into consideration pre-menopausal versus post-menopausal patients' needs. The primary outcomes of interest are the incidences of invasive and non-invasive breast cancer.

This is a clinical practice guideline for patients with non-melanoma skin cancer. The guideline discusses prevention, staging, treatment, and follow-up for these patients. Specific diseases discussed include basal cell carcinoma, squamous cell carcinoma, keratoacanthomas, Merkel cell tumours, Kaposi's sarcoma, extramammary Paget's disease (EMPD), and other non-melanoma skin cancers. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This clinical practice guideline for patients with suspected or confirmed non-epithelial ovarian cancer. The guideline discusses the prevention, diagnosis, staging, management, and follow-up of these patients. Specific conditions discussed include sex cord stromal tumours (SCSTs), and germ cell tumours (GCTs). Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for children with cancer who are being treated with chemotherapy, and/or children who are receiving hematopoietic stem cell transplantation (HSCT). The guideline provides recommendations on systemic antibacterial prophylaxis for the prevention of common invasive bacterial infections in these patients. Outcomes of interest include the risk of bacteremia, and infection-related mortality.

This is a clinical practice guideline for the prevention and treatment of venous thromboembolism (VTE) in adult patients with cancer. The guideline discusses the prophylaxis of VTE in patients who have undergone surgery, prophylaxis of catheter-related thrombosis, treatment of established VTE, and maintenance treatment (both early and long-term). Risk-stratification schemes for the prophylaxis of VTE in patients with cancer, are also examined.

This is a clinical practice guideline for the management of epithelial precancerous conditions and lesions in the stomach. The guideline specifically addresses the diagnostic assessment, treatment and surveillance of individuals with atrophic gastritis, intestinal metaplasia, and dysplasia of the stomach. Topics discussed include endoscopic diagnosis, biopsies and histology, noninvasive assessment, management, Helicobacter pylori treatment, follow-up, and the cost-effectiveness of surveillance and screening.

This is a clinical practice guideline for patients who are at an increased risk of developing colorectal cancer (CRC), due to hereditary factors. The guideline examines the management of these patients, including the prevention of CRC, diagnosis of CRC, endoscopic management, and surgical care. Specific hereditary conditions discussed include Lynch syndrome, Lynch-like syndrome, serrated polyposis syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, and juvenile polyposis syndrome. Outcomes of interest include decreasing the lifetime risk of developing CRC, decreasing morbidity due to CRC or its treatment, as well as improving the identification of hereditary CRC syndromes.

This is a guideline for the prevention, screening/early detection, diagnosis, staging, and management of breast cancer. Management options for early invasive breast cancer, stage I or II tumours, locally advanced breast cancer, inflammatory breast cancer, locoregional recurrence, metastatic breast cancer and special circumstances in breast cancer patients are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for patients with chemotherapy-induced peripheral neuropathy (CIPN). The guideline provides a framework for the screening, assessment and management of CIPN. Assessment tools, rehabilitation strategies, pharmacologic management options, and referral to specialists are addressed.

This is a clinical practice guideline for the prevention and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), in adult patients with cancer. The guideline discusses whether anticoagulation is appropriate for the prophylaxis of VTE in hospitalized patients with cancer, ambulatory patients with cancer who are receiving systemic chemotherapy, and patients who are undergoing surgery (i.e. preoperatively). Risk prediction, awareness of VTE among patients, and the optimal methods for treating established VTE, are also discussed.

This is a clinical practice guideline for patients who have been diagnosed with melanoma, and those who are at high risk for melanoma. The guideline provides recommendations on prevention, screening of high risk individuals, diagnosis, staging, treatment, and follow-up. Treatment strategies explored include surgery, radiation therapy, and adjuvant chemotherapy, and recommendations are separated based on disease type. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a guideline for the prevention, screening/early detection, diagnosis, staging, and management of endometrial cancer. Management options examined include surgery, adjuvant therapy (e.g. pelvic radiotherapy, chemotherapy), and estrogen replacement therapy. Recommendations for follow-up are presented based on the type of treatment chosen. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for physicians who work on the prevention and treatment of colorectal cancer in the ambulatory and inpatient sector. The guideline provides recommendations for prevention, screening in asymptomatic populations as well as high risk populations, the role of endoscopy in the diagnosis of polyps and colorectal cancer, pre-operative diagnostics and surgery, adjuvant and neoadjuvant therapy, management of patients with metastases, palliative care and follow-up care.

This is a clinical practice guideline for adults and children with tumours or hematological cancers who are undergoing chemotherapy and/or other systemic therapies. The guideline provides recommendations for influenza vaccination in these patients. Outcomes of interest include post-vaccine frequency of immune-related adverse events, other infection-related adverse events, and mortality.

This is a clinical practice guideline for the diagnosis and treatment of anal intraepithelial neoplasia (AIN). Diagnostic elements discussed include clinical evaluation with associated digital rectal examination (DARE), as well as brushing and viral typing, anoscopy, and biopsy. For the treatment of AIN, the guideline examines topical treatments such as imiquimod, 5-fluorouracil (5-FU), cidofovir and trichloroacetic acid (TCA), as well as ablative methods, including electrocautery, radiofrequency ablation (RFA), CO2 laser therapy, infrared coagulation (IRC), photodynamic therapy and surgery. The primary outcome of interest is the prevention of squamous cell carcinoma (SCC).

This is a clinical practice guideline for patients who have been diagnosed with or who are at high risk for hepatocellular carcinoma (HCC). The guideline provides recommendation for the primary, secondary, or tertiary prevention of HCC, the surveillance of patients who are at high risk for developing HCC, the diagnosis and staging of HCC, as well as the treatment and follow-up of patients with HCC. Surgery and radiation therapy are the primary treatment modalities discussed.

This is a clinical practice guideline for women with cervical intraepithelial neoplasia (CIN). Recommendations are provided on the use of thermal ablation for the treatment of these women, with the ultimate goal of reducing the incidence of cervical cancer. The guideline compares thermal ablation to other treatment approaches such as cryotherapy, large loop excision of the transformation zone (LLETZ), and cold knife conization (CKC). Different modalities of thermal ablation (e.g., those that differ by temperature, number of applications, duration, etc.) are also discussed.

This is a clinical practice guideline for patients who have undergone hematopoietic stem cell transplantation (HSCT), and/or those who are receiving other types of therapy for hematological malignancies. The guideline examines the prevention, diagnosis, and management of cytomegalovirus (CMV) infection in these patients. The primary outcomes of interest are CMV serostatus and survival.

This is a clinical practice guideline for patients with sarcoma or connective tissue tumours, including bone tumours. The guideline provides recommendations addressing prevention, diagnosis, staging, management, and follow-up. Diagnostic pathology, as well as treatment through chemotherapy, radiotherapy, and surgery are specifically discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This clinical practice guideline is focused on the prevention, classification, diagnosis, staging, and management of ovarian epithelial carcinoma. Management options considered include surgery, chemotherapy, radiation therapy (for palliation), and approaches for fertility management. This guideline also discusses hereditary cancer syndromes, tumours of low malignant potential, estrogen replacement therapy, management of serous tubal intraepithelial carcinoma (STIC), and follow-up of patients after treatment. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This clinical practice guideline is an endorsement of the American Society of Clinical Oncology’s 2017 guideline titled Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. The guideline discusses the use of antiemetics for the prevention and management of nausea and vomiting in adult patients undergoing chemotherapy and/or radiotherapy. Various treatment regimens are examined based on the frequency of emesis. Other topics of interest include the use of adjunctive drugs, cannabinoids, as well as other complementary and alternative therapies.

This is a clinical practice guideline for adult patients with keratinocyte cancer (KC). The guideline examines the prevention, screening, diagnosis, treatment, and follow-up of these patients. Treatment options considered include surgery, radiotherapy, cryotherapy, topical treatments, and photodynamic therapy. Organ transplantation and conditions associated with immunosuppression are also discussed, as are systemic therapies for metastatic disease, the role of primary care, the economics of KC, and common concerns raised by patients. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of January 15, 2020.

This is a clinical practice guideline for patients with post-colonoscopy colorectal cancer (PCCRC) or post-imaging colorectal cancer (PICRC). The guideline examines the identification, analysis, and reporting of these cancers. Methods for assessing an individual PCCRC case, methodology for assessing PCCRC rates across services, and non-colonoscopic imaging of the colon are discussed. The prevention of PCCRC and PICRC in high-risk groups is also addressed.

This is a clinical practice guideline for the prevention and treatment of clostridium difficile infection (CDI) in children and adolescents with cancer as well as in pediatric hematopoietic stem-cell transplantation (HSCT) patients. The guideline provides initial treatment recommendations for non-severe, severe and recurrent CDI. The efficacy and appropriateness of probiotics, monoclonal antibodies and fecal microbiota transplantation are also considered.

This is a clinical practice guideline for women who are at increased risk of developing breast cancer. The guideline examines the elements of risk, risk assessment, risk-reduction interventions, and the components of risk-reduction counselling. Risk-reduction interventions considered are lifestyle modifications, risk-reduction surgery, and risk-reduction agents including Tamoxifen, Raloxifene, and Aromatase. Monitoring patients on risk reduction agents, and managing the side effects of these agents are also discussed.

This is a clinical practice guideline for adult and pediatric patients with cancer. The guideline examines influenza immunization in these patients, including recommended vaccine, dosing, as well as the effect of age, duration, and systemic therapy on the patient's response to the vaccination. Patients undergoing hematopoietic stem cell transplant (HSCT) are further discussed, as is the immunization of individuals in contact with these patients.

This is a clinical practice guideline for adults and children who have undergone hematopoietic stem cell transplantation (HSCT). The guideline provides recommendations for the prevention, diagnosis, and treatment of BK polyomavirus-associated (BKPyV-associated)hemorrhagic cystitis. Outcomes of interest include post-HSCT morbidity, mortality, and quality of life.

This is a clinical practice guideline for children undergoing treatment for leukemia, or other forms of cancer. The guideline examines strategies for the prevention, assessment, and treatment of venous thromboembolism (VTE). Management of thrombocytopenia and coagulopathy, as well as therapy options for menstrual suppression, are also discussed.

This is a clinical practice guideline for women who are at increased risk of developing breast cancer. The guideline examines the elements of risk, risk assessment, risk-reduction interventions, and the components of risk-reduction counselling. Risk-reduction interventions considered are lifestyle modifications, risk-reduction surgery, and risk-reduction agents including Tamoxifen, Raloxifene, Aromatase, Anastrozole and Exemestane. Monitoring patients on risk reduction agents, and managing the side effects of these agents are also discussed.

This is a clinical practice guideline for adults with cancer who are at risk for, or have been diagnosed with, delirium. The guideline provides recommendations regarding delirium prevention, diagnosis, screening, treatment and experiential impact. Pharmacological and non-pharmacological interventions are discussed. Guidance is also provided on education and support for the healthcare team and family members.

This is a clinical practice guideline for the prevention and screening of skin cancer. Behavioural counselling recommendations are provided for young adults, adolescents, children, and parents of young children. Outcomes of interest include changes in sun protection behaviours, frequency of sunburn, and frequency of skin cancer.

This is a clinical practice guideline for patients with central nervous system (CNS) diffuse large B-cell lymphoma who have or at risk of developing leptomeningeal and/or brain parenchyma lymphoma relapse. The guideline examines the treatment of central nervous system involvement of lymphoma using whole-brain radiotherapy, systemic chemotherapy, intensification chemotherapy and autologous hematopoietic stem cell transplantation, and intrathecal therapy. Risk factors, diagnostic screening, and CNS prophylaxis are also discussed.

This is a clinical practice guideline for the management of muscle-invasive and metastatic bladder cancer. The guideline provides recommendations on prevention, staging, imaging, diagnosis, treatment, and follow-up. Treatment options such as neoadjuvant chemotherapy, radiotherapy, and radical surgery are discussed. Other topics of interest include risk factors, comorbidities, quality of life, and pelvic organ preservation techniques.

This is a clinical practice guideline for adult patients with hematological malignancies, especially those receiving remission-induction therapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The guideline examines the primary prophylaxis of invasive fungal infections (IFI) in these patients using a variety of medications. Other topics discussed include newly developed targeted cancer therapies and their effects on risk of IFI, as well as the effects of therapeutic drug monitoring on the efficacy and safety of antifungal prophylaxis.

This is a clinical practice guideline for patients with multiple myeloma (MM). The guideline provides recommendations for the prevention and management of organ health-related toxicities, and gives best practice recommendations for optimal nursing care of this patient population. Specific outcomes examined include myeloma-induced renal impairment, gastrointestinal symptoms, and peripheral neuropathy.

This is a clinical practice guideline for adults who have been diagnosed with or are suspected of having basal cell carcinoma (BCC). The main focus of the guideline is on the most common approaches for the treatment of primary BCC, but it also includes recommendations on the treatment of recurrent tumours, appropriate biopsy techniques, staging, follow-up, and prevention of BCC.

Tailored to the unique needs and concerns of patients with all types of cancer, this clinical practice guideline provides standard-of-care recommendations, techniques, and strategies on smoking cessation. The guideline outlines different interventions, including pharmacotherapy options (e.g. nicotine replacement therapy, varenicline, bupropion, nortriptyline, clonidine), motivational strategies and behaviour techniques, and alternative treatment approaches such as electronic cigarettes and other electronic nicotine delivery systems.

This is a clinical practice guideline for patients with epithelial ovarian-type cancers (e.g. ovary, fallopian tube or peritoneal origin) and borderline tumours. This guideline addresses epithelial cancers of varying histological subtypes. The guideline covers the full continuum of care including screening and prevention, diagnosis, treatment options such as surgery, systemic therapy and chemotherapy, follow-up, as well as management of recurrent disease. The guideline also highlights the support needs for women with ovarian cancer.

This is a clinical practice guideline for patients with actinic keratosis (AK). The guideline provides recommendations on treatment options such as topical therapies, cryosurgery, surgery, systemic therapy, photodynamic therapy, laser therapy, and combination treatment. Diagnosis and follow-up are also discussed.

This is a clinical practice guideline for women with uterine cancer. The guideline provides recommendations for the screening and prevention of uterine cancer in the general population and in high risk groups, as well as for the pathological work-up, management, and follow-up of patients with uterine cancer. Specific conditions discussed include endometrioid endometrial cancer, as well as non-endometrioid cancers such as uterine serous carcinoma, uterine clear cell carcinoma, and uterine carcinosarcoma.

This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the care of these patients throughout the cancer care continuum, including prevention and surveillance, diagnosis and prognosis, surgical management and staging, further investigations and non-surgical staging, adjuvant treatment of stage 2 and 3 melanoma, follow up of patients with stage 1, 2 and 3 melanoma, and management of advanced (unresectable stage 4 or 5) melanoma.

This is a clinical practice guideline for patients with Lynch syndrome (LS). The guideline examines screening, prevention, and treatment of cancer in these patients. Specifically, screening tests for endometrial, ovarian, gastric, small intestinal, pancreatic, breast, and prostate cancers, as well as cancers of the urinary tract, are discussed. Prophylactic hysterectomy and oophorectomy, tumour testing, germline testing, and LS management are also examined.

This is a clinical practice guideline for adults and children with hematologic malignancies, solid tumours, or hypoproliferative thrombocytopenia. The guideline examines when and how clinicians should use platelet transfusion to prevent or manage bleeding in these patients. Recommendations are made on topics such as the preparation of platelet products, the prevention of Rhesus (Rh) alloimmunization, and platelet transfusion thresholds for patients with different conditions.

This is a clinical practice guideline for patients with incidentally detected gallbladder polyps. The guideline examines the management and follow-up of these patients. Specific topics addressed include which patients require cholecystectomy, which patients require ultrasound follow-up, and what the frequency and duration of follow-up should be.

This is a clinical practice guideline for patients with colorectal polyps. The guideline examines the use of polypectomy and endoscopic mucosal resection (EMR) in colonoscopy and for colorectal cancer (CRC) prevention. Polyp classification, polypectomy for polyps smaller than 20mm, EMR for polyps 20mm or larger, technical considerations, adverse events, and histopathology are discussed.

This is a clinical practice guideline for children with cancer who are receiving chemotherapy and/or radiation therapy. Recommendations are provided for the prevention of mucositis through oral care management, and various treatment options are considered for the management of mucositis in affected patients. The guideline also lists the risk factors for mucositis, and provides an oral assessment tool.

This clinical practice guideline provides recommendations for breast reconstruction in women following mastectomy for the prevention or treatment of breast cancer. The guideline discusses patient education, eligibility for reconstruction, timing of reconstruction, factors that enhance recovery from reconstruction, post-reconstruction surveillance, and measuring outcomes of construction. The benefits and risks of implant-based, autologous flap, and combination reconstruction procedures are examined. The guideline also discusses the extent to appropriately perform mastectomy.

This is a clinical practice guideline for the vaccination of human papillomavirus (HPV) for the prevention of cervical cancer in women. The guideline examines the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the cross-protective ability of each HPV preventive vaccine.

This is a clinical practice guideline for adult patients with non-small cell lung cancer. The guideline provides updated recommendations around prevention and screening, evaluation and staging, treatment, and follow up care. Areas of focus are discussed with recognition that much progress has been made in regards to screening, minimally invasive techniques for diagnosis and treatment, advances in radiation therapy (RT) including stereotactic ablative radiotherapy (SABR), and targeted therapies.

This is a clinical practice guideline for females and males between the ages of 9 and 26. The guideline examines the use of the human papillomavirus (HPV) vaccination for the purposes of cancer prevention. The ages at which routine vaccination and catch-up vaccination should occur are discussed, as well as which vaccines should be used for males and females. Special populations such as men who have sex with other men and immunocompromised persons are also addressed.

This is a clinical practice guideline for patients with myeloproliferative neoplasms (MPN). The guideline examines the diagnosis, management, and prevention of severe bleeding complications in patients diagnosed with classic Philadelphia chromosome negative (Ph-negative) MPN. Bleeding due to alterations of primary hemostasis, secondary hemostasis, and vascular alterations are discussed. Management of elective surgery in MPN patients is also examined.

This is a clinical practice guideline for patients who have undergone allogenic hematopoietic stem cell transplantation (HSCT). The guideline examines the prevention, diagnosis and management of post-lymphoproliferative disorders caused by Epstein-Barr virus (EBV) infections in these patients. Outcomes of interest include the sensitivity and specificity of tests that detect EBV-related post-transplant lymphoproliferative disorders, and the reduction of morbidity and mortality in patients undergoing HSCT.

This clinical practice guideline provides recommendations on influenza vaccinations for children and adults with solid tumours or hematologic malignancies. Recommendations are provided for vaccine type (live versus inactivated) and administration in relation to the therapy cycle, and are stratified by patient age (adult versus pediatric). Topics of discussion include the effects of age, duration, and type of systemic therapy in regards to response of patients to the influenza vaccine, as well as contraindications and precautions for immunization.

This is a clinical practice guideline for the screening and treatment of precancerous lesions for cervical cancer prevention. The guideline focuses specifically on the screening for cervical intraepithelial neoplasia 2 & 3 and the treatment of those lesions to prevent cervical cancer in women who tested positive after screening. In formulating the recommendations, the guideline authors specifically took into account resource implications in the Saudi context.

This clinical practice guideline examines the impact of fertility drugs on the risk of cancer in women. The guideline looks at the association between use of fertility drugs and increased risk of developing invasive ovarian, breast, endometrial, colon and thyroid cancers as well as non-Hodgkin lymphoma and malignant melanoma. The association between fertility drugs and borderline ovarian tumours is also examined.

This is a clinical practice guideline for women who are at increased risk of developing breast cancer. The guideline provides an overview on risk assessment, risk-reduction interventions including lifestyle interventions, risk-reduction surgery, and risk-reduction agents (tamoxifen, raloxifene, aromatase inhibitors). Recommendations are also provided for managing side effects of risk-reduction agents and monitoring for complications. Risk-reduction counselling is also discussed.

This is an update to the 2009 recommendation on aspirin use to prevent cardiovascular disease (CVD) events and the 2007 recommendation on aspirin and nonsteroidal anti-inflammatory drug use to prevent colorectal cancer (CRC). The recommendations apply to adults aged 40 years or older without known CVD and without increased bleeding risk. Recommendations include consideration of the aspirin dosage as well as the benefits and harms of initiating aspirin use.